secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001437749-25-029005
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports positive long-term neurological data for ALXN1840 in Wilson disease
--------------------------------------------------------------------------------

- Pooled efficacy from 3 trials (n=255) showed sustained neurological improvement on UWDRS Part II & III over 6 years.
- Patients crossing from standard of care to ALXN1840 showed additional neurological improvement, reversing prior worsening.
- Psychiatric improvement sustained over multiple years per Brief Psychiatric Rating Scale (BPRS).
- Safety: <1% drug-related neurological serious adverse events across >645 patient-years on ALXN1840.
- Data presented at ANA Annual Meeting; builds on hepatic efficacy data from EASL 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925029005/0001437749-25-029005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925029005/mnpr20250912_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer